[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352068-105":59,"doc-detail-352068-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","closing-the-translational-gap-closed-loop-ai-discovery-frameworks-for-experimental-validation-and-clinical-implementation-in-cancer-therapeutics","Closing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics","","Novel cancer therapeutic development remains slow and expensive, with high attrition driven by tumor heterogeneity and acquired resistance. Artificial intelligence supports target discovery, de novo candidate design, and biomarker identification using multimodal data, yet a persistent validation gap limits clinical value. Models can hallucinate chemically implausible compounds, overfit biased datasets, and degrade outside training distributions. Landmark analyses show success when AI is constrained by synthetic accessibility and functional genomic screening, with dose and combination hypotheses validated in patient-derived xenografts. Closed-loop frameworks iteratively retrain on experimental outcomes, accelerating delivery of more effective, personalized therapies validated across in vitro, in vivo, and prospective clinical trial stages.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/closing-the-translational-gap-closed-loop-ai-discovery-frameworks-for-experimental-validation-and-clinical-implementation-in-cancer-therapeutics/352068/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/closing-the-translational-gap-closed-loop-ai-discovery-frameworks-for-experimental-validation-and-clinical-implementation-in-cancer-therapeutics/352068.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does a validation gap persist in AI-driven cancer drug discovery?","Question",{"text":112,"@type":113},"AI models often accumulate in silico predictions without systematic biological testing. This leads to outputs that fail because models learn artifacts rather than underlying biology.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problems limit clinical translation of AI models?",{"text":117,"@type":113},"Models may generate hallucinated, chemically implausible molecules and can overfit biased training datasets such as immortalized cell lines. Predictions also tend to perform poorly outside the training distribution.",{"name":119,"@type":110,"acceptedAnswer":120},"How do closed-loop AI discovery frameworks address translational challenges?",{"text":121,"@type":113},"Experimental outcomes iteratively retrain computational models, constraining and refining target discovery and therapeutic predictions. This supports validation across in vitro assays, patient-derived xenografts, and prospective clinical trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352068,1790341031,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Medicine   \n SPECIAL ISSUE  Artificial Intelligence in Cancer Care  \nREVIEW  OPEN ACCESS   \nClosing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics  \nTuğba Ören Varol1  | Mehmet Varol2   \n1Department of Chemistry, Faculty of Science, Kotekli Campus, Mugla Sitki Kocman University, Mugla, Turkey | 2Department of Molecular Biology and Genetics, Faculty of Science, Kotekli Campus, Mugla Sitki Kocman University, Mugla, Turkey  \nCorrespondence: Mehmet Varol ([mehmetvarol@mu.edu.tr](mehmetvarol@mu.edu.tr))  \nReceived: 17 February 2026 | Revised: 8 July 2026 | Accepted: 11 August 2026  \nKeywords: artificial intelligence | biomarker discovery | drug design | experimental validation | machine learning  \nABSTRACT  \nThe development of novel cancer therapeutics is a protracted, costly endeavor with high attrition rates, largely attributed to tumor heterogeneity and acquired resistance. Artificial intelligence (AI) is emerging as a powerful technology to enhance the drug discovery pipeline, employing multimodal datasets to identify therapeutic targets, design de novo candidates, and discover biomarkers. However, a significant validation gap persists. AI models frequently hallucinate chemically implausible molecules, overfit to biased training datasets (particularly immortalized cell lines that poorly represent patient tumors), and generate predictions that perform poorly outside their training distribution. This gap exists because AI development has prioritized algorithmic sophistication over experimental rigor, creating an accumulation of in silico predictions without systematic biological testing. Analysis of landmark studies reveals that AI-driven target discovery is most successful when constrained by synthetic accessibility filtersand functional genomic screening, while dose optimization and combination therapy predictions require validation in patientderived xenografts (PDXs) that recapitulate tumor microenvironment complexity. The most clinically impactful AI applications in oncology, from immunotherapy biomarker discovery to resistance mechanism prediction, tend to employ closed-loop discovery frameworks in which experimental outcomes iteratively retrain computational models. We propose that the translational potential ofAI in oncology is not solely defined by algorithmic complexity, but substantially shaped by the rigor of the experimental feedback loops that constrain and refine it, thereby accelerating the delivery of more effective, personalized therapies validated through the complete hierarchy of in vitro assays, in vivo PDX models, and prospective clinical trials to patients.  \n1 | Introduction  \nDespite decades of investment, oncology drug development retains the highest attrition rates in medicine. Among cancer drugs entering Phase I clinical trials, only approximately 5% ultimately receive U.S. Food and Drug Administration (FDA) approval, the lowest success rate across all therapeutic areas [1] . Most failures occur in late-stage Phase II and III trials after substantial time and resources have been invested, reflecting poor target validation and incomplete understanding of the biological  \nsystems being targeted [1, 2]. These failures represent not merely economic loss but delayed access to potentially life-saving treatments. Cancer's inherent biological complexity, intratumor heterogeneity and adaptive resistance mechanisms, generates high-dimensional, multimodal data patterns that exceed human pattern recognition capacity [3] . Traditional hypothesis-driven approaches struggle to integrate genomic, transcriptomic, proteomic, clinical, and imaging data simultaneously [4] . Cancer presents a dimensionality problem that conventional methodologies cannot efficiently solve.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction i","cbCaioZGireqWM8s","https://ap.wps.com/l/cbCaioZGireqWM8s","pdf",2313985,23,"English","# Abstract\n# Introduction\n## Epistemological barriers and validation gap\n## Closed-loop discovery and experimental feedback","[{\"question\":\"Why does a validation gap persist in AI-driven cancer drug discovery?\",\"answer\":\"AI models often accumulate in silico predictions without systematic biological testing. This leads to outputs that fail because models learn artifacts rather than underlying biology.\"},{\"question\":\"What problems limit clinical translation of AI models?\",\"answer\":\"Models may generate hallucinated, chemically implausible molecules and can overfit biased training datasets such as immortalized cell lines. Predictions also tend to perform poorly outside the training distribution.\"},{\"question\":\"How do closed-loop AI discovery frameworks address translational challenges?\",\"answer\":\"Experimental outcomes iteratively retrain computational models, constraining and refining target discovery and therapeutic predictions. This supports validation across in vitro assays, patient-derived xenografts, and prospective clinical trials.\"}]","Closing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics | PDF",1790097537,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4818fe1f3d6cca4ea1511f13d837fc0e.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08053c490ba0f3228773c0d15e667050.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c61f1939b6d22084a682bef5feac2bd8.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/290361584c4d30b5013ff2d37eaef26a.webp",980,1287]